ERBB2 and triple-negative breast carcinoma: Moreover, 208 patients presented with luminal A (27.55%), 74 with luminal B (9.80%), 116 with HER2-positive (15.36%), and 357 with triple-negative breast cancer (TNBC) (47.28%) subtypes.